molnupiravir Side Effects
Also known as: Lagevrio
Analysis of 5,119 adverse event reports submitted to the FDA from 2018 to 2025.
Total Reports
5,119
Death-Related
472
9.2% of reports
Hospitalizations
933
18.2% of reports
Top Indication
Covid-19 Treatment
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 472 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| COVID-19 | 131 |
| DEATH | 103 |
| PNEUMONIA ASPIRATION | 39 |
| PNEUMONIA | 34 |
| RESPIRATORY FAILURE | 29 |
| COVID-19 PNEUMONIA | 28 |
| DECREASED APPETITE | 25 |
| DRUG INEFFECTIVE | 24 |
| PRODUCT USE ISSUE | 22 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 20 |
| HAEMATEMESIS | 18 |
| NAUSEA | 18 |
| CARDIAC FAILURE | 16 |
| CARDIAC ARREST | 14 |
| DIARRHOEA | 14 |
| DYSPHAGIA | 14 |
| ABDOMINAL DISCOMFORT | 13 |
| CONDITION AGGRAVATED | 11 |
| MARASMUS | 11 |
| SEPSIS | 11 |
Reactions in Hospitalization Reports
Top reactions in 933 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| COVID-19 | 258 |
| DRUG INEFFECTIVE | 69 |
| COVID-19 PNEUMONIA | 67 |
| PNEUMONIA | 58 |
| DIARRHOEA | 53 |
| ADVERSE EVENT | 46 |
| PRODUCT USE ISSUE | 42 |
| VOMITING | 40 |
| CONDITION AGGRAVATED | 34 |
| NAUSEA | 34 |
| OXYGEN SATURATION DECREASED | 32 |
| PYREXIA | 31 |
| DECREASED APPETITE | 30 |
| PNEUMONIA ASPIRATION | 30 |
| OFF LABEL USE | 27 |
| DYSPHAGIA | 24 |
| HOSPITALISATION | 22 |
| DEHYDRATION | 20 |
| ANAEMIA | 19 |
| DYSPNOEA | 19 |
Nearby — Related Medications
What the FAERS Data Reveals About molnupiravir Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 5,119 voluntary reports linked to molnupiravir and its brand equivalents (Lagevrio), spanning 2018 through 2025. Of those, 472 (9.2%) listed death as an outcome and 933 (18.2%) involved hospitalization. The most common indication reported alongside adverse events was Covid-19 Treatment.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 55% were female and 45% male; age distribution skews toward 75+, with 1,840 reports in that bracket. The single most reported reaction is product use issue with 709 submissions, followed by no adverse event and covid-19.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.